——
Real-time prices · US MarketsHealthy balance sheet and financial position.
weak profitability metrics drag quality score.
Quality
4.4
Health
5
Growth
5
Valuation
5
Sentiment
5
Analyst Target
—
Price Chart
Data not available.
Latest News
- All You Need to Know About Novartis (NVS) Rating Upgrade to Buy
- Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered Capsids
- Global Gene Silencing Therapeutics Market Report 2026-2030 | Capitalize on 16.3% CAGR as Novartis, Alnylam, Ionis, Sarepta, and Arrowhead Accelerate RNA Delivery
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
—
next 12 months est.
Market Cap
—
market capitalization
Div Yield
—
dividend yield
Profit Margin
—
net profit margin
Gross Margin
—
revenue minus COGS
ROE
—
return on equity
Beta
—
vs S&P 500
52-Week Range
—
annual min — max
Frequently Asked Questions
What do analysts say about NOVA right now?
NOVA's Q·Score is 4.8/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Healthy balance sheet and financial position. Key area to monitor: weak profitability metrics drag quality score. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
Is NOVA overvalued or undervalued?
NOVA (NOVA) scores in line with sector averages on valuation metrics.